Inflammation-based prognostic scores predict the prognosis of locally advanced cervical esophageal squamous cell carcinoma patients receiving curative concurrent chemoradiotherapy: A propensity score-matched analysis

Chia-Che Wu 1, Shau-Hsuan Li 1, Hung-I Lu 2, Chien-Ming Lo 2, Yu-Ming Wang 3, Shang-Yu Chou 3, Yen-Hao Chen

1 Department of Hematology-Oncology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Kaohsiung, Taiwan
2 Department of Thoracic & Cardiovascular Surgery, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Kaohsiung, Taiwan
3 Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Kaohsiung, Taiwan
4 Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taoyuan, Taiwan
5 School of Medicine, Chung Shan Medical University, Taichung, Taichung, Taiwan

Corresponding Author: Yen-Hao Chen
Email address: alex2999@cgmh.org.tw

Introduction: The present study investigated the crucial role of inflammation-based prognostic scores in locally advanced cervical esophageal squamous cell carcinoma (ESCC) patients who underwent curative concurrent chemoradiotherapy (CCRT).

Methods: There were 411 ESCC patients enrolled, including 63 cervical ESCC patients. Using the propensity score matching method, 63 thoracic ESCC patients were matched to the 63 cervical ESCC patients. The inflammation-based prognostic scores included the neutrophil lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR), albumin level, c-reactive protein (CRP) level, modified Glasgow prognostic score (mGPS), and CRP/albumin ratio. The chi-square test and Kaplan-Meier method were used for categorical variable data and overall survival, respectively. A Cox regression model was performed for univariate and multivariable analyses.

Results: With respect to cervical ESCC, NLR ≥ 2.5 (P=0.019), PLR ≥ 103 (P=0.013), CRP value > 10 mg/l (P=0.040), mGPS ≥ 1 (P=0.040), and CRP/albumin ratio ≥ 9.5 (P=0.033) were significant predictors of worse overall survival (OS) in the univariate analysis. In a multivariable analysis, PLR ≥ 103 (P=0.010, HR: 2.66, 95% CI: 1.27-5.58) and mGPS ≥ 1 (P=0.030, HR: 2.03, 95% CI: 1.07-3.86) were the independent prognostic parameters of worse OS. The prognostic value of these biomarkers in the matched thoracic ESCC patients was similar and compatible with the results in the cervical ESCC group in the univariate and multivariable analyses.

Conclusions: Our study suggests that these inflammation-based prognostic scores are helpful in clinical practice, and PLR and mGPS may predict the prognosis for locally advanced cervical ESCC patients who receiving curative CCRT.
Inflammation-based prognostic scores predict the prognosis of locally advanced cervical esophageal squamous cell carcinoma patients receiving curative concurrent chemoradiotherapy: A propensity score-matched analysis

Chia-Che Wu, MD¹#, Shau-Hsuan Li, MD¹#, Hung-I Lu, MD,² Chien-Ming Lo, MD,² Yu-Ming Wang, MD,³ Shang-Yu Chou, MD,³ and Yen-Hao Chen, MD,¹,4,5*

Affiliations:

¹Department of Hematology-Oncology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan

²Department of Thoracic & Cardiovascular Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan

³Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan

⁴Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan
School of Medicine, Chung Shan Medical University, Taichung, Taiwan

# These authors contributed equally to the work

*Correspondence: Yen-Hao Chen, MD, Department of Hematology-Oncology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.

No.123, Dapi Rd., Niaosong Dist., Kaohsiung City 833, Taiwan (R.O.C.)

Tel: 886-7-7317123 ext.8303, Fax: 886-7-7322402,

E-mail: alex8701125@gmail.com
Abstract

Introduction: The present study investigated the crucial role of inflammation-based prognostic scores in locally advanced cervical esophageal squamous cell carcinoma (ESCC) patients who underwent curative concurrent chemoradiotherapy (CCRT).

Methods: There were 411 ESCC patients enrolled, including 63 cervical ESCC patients. Using the propensity score matching method, 63 thoracic ESCC patients were matched to the 63 cervical ESCC patients. The inflammation-based prognostic scores included the neutrophil lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR), albumin level, c-reactive protein (CRP) level, modified Glasgow prognostic score (mGPS), and CRP/albumin ratio. The chi-square test and Kaplan–Meier method were used for categorical variable data and overall survival, respectively. A Cox regression model was performed for univariate and multivariable analyses.

Results: With respect to cervical ESCC, NLR ≥ 2.5 (P=0.019), PLR ≥ 103 (P=0.013), CRP value > 10 mg/l (P=0.040), mGPS ≥ 1 (P=0.040), and CRP/albumin ratio ≥ 9.5 (P=0.033) were significant predictors of worse overall survival (OS) in the univariate analysis. In a multivariable analysis, PLR ≥ 103 (P=0.010, HR: 2.66, 95% CI: 1.27-5.58) and mGPS ≥ 1 (P=0.030, HR: 2.03,
95% CI: 1.07-3.86) were the independent prognostic parameters of worse OS. The prognostic value of these biomarkers in the matched thoracic ESCC patients was similar and compatible with the results in the cervical ESCC group in the univariate and multivariable analyses.

Conclusions: Our study suggests that these inflammation-based prognostic scores are helpful in clinical practice, and PLR and mGPS may predict the prognosis for locally advanced cervical ESCC patients who receiving curative CCRT.

Introduction

Esophageal cancer is one of the most fatal human malignancies worldwide. In Taiwan, esophageal squamous cell carcinoma (ESCC) is the major pathologic type of esophageal cancer, accounting for more than 90% of all cases, and is the ninth leading cause of cancer-related deaths (National Department of Health, Republic of China, 2015). The cervical esophagus is a small portion of the esophagus with a length of 5 cm, and cervical ESCC accounts for only a small portion, specifically, less than 10%, of all esophageal cancer cases (Yin et al., 1983). In the past, the standard treatment for cervical ESCC was radical surgery, radiotherapy, or a combination of both. However, the surgery usually consisted of laryngoesophagectomy and reconstruction with
gastric transposition or colon graft. Moreover, even with such surgery, the 5-year survival rate was only 12% to 27% and the post-operative mortality rate was high at 6% to 20% with significant morbidities (Grass et al., 2015). Recently, however, several studies have shown that concurrent chemotherapy (CCRT) improves survival rates for ESCC and head/neck cancer patients; therefore, some physicians preferred definitive CCRT rather than surgical resection for cervical ESCC patients in clinical practice, especially for locally advanced status (Cooper et al., 1999; Pignon et al., 2009).

Growing evidences have revealed that inflammation plays an important role in tumor cell proliferation, migration, invasion, and metastasis, as well as disease progression (Balkwill & Mantovani, 2001; Mantovani et al., 2008). A series of inflammatory biomarkers, such as the neutrophil lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR), albumin level, c-reactive protein (CRP) level, modified Glasgow prognostic score (mGPS), and CRP/albumin ratio, have been identified to predict clinical outcomes in several cancer types, including esophageal cancer (Feng et al., 2014; Lindenmann et al., 2014; Pinato et al., 2014; Stotz et al., 2013; Templeton et al., 2014; Yodying et al., 2016).
With respect to esophageal cancer, these biomarkers were reported to be associated with tumor progression and prognosis in esophageal cancer patients who receive different therapeutic modalities, including surgical resection, neoadjuvant chemoradiotherapy followed by esophagectomy, esophagectomy followed by adjuvant chemoradiotherapy, and definitive chemoradiotherapy (Dutta et al., 2011; Feng et al., 2013; Miyata et al., 2011; Sharaiha et al., 2011; Yoo et al., 2014). However, to the best of our knowledge, these biomarkers have not been evaluated in cervical ESCC patients who receive curative CCRT.

In the present study, the locally advanced cervical ESCC patients who received curative CCRT in our hospital were retrospectively reviewed, and the aim of the study was to determine the clinical impact of inflammation-based prognostic scores in locally advanced cervical ESCC patients who have undergone curative CCRT.

Material and Methods

Patient population

Study approval was obtained from the Chang Gung Medical Foundation Institutional Review Board (201800845B0), and written informed consent from the patients or their families.
was not judged necessary for this kind of retrospective study. We retrospectively reviewed ESCC patients with available medical records who underwent treatment between January 2005 and December 2015 at Kaohsiung Chang Gung Memorial Hospital. The eligibility criteria were as follows: (1) squamous cell carcinoma in histology; (2) locally advanced status, stage III, without distant metastasis or neck/celiac lymph node metastasis; (3) complete CCRT with curative intent; (4) survive more than 3 months after completing CCRT; (5) no history of second primary malignancy, such as head and neck cancers; (6) no form of any acute or chronic infection/inflammatory disease; and (7) Eastern Cooperative Oncology Group performance status 0-1. Ultimately, there were 411 ESCC patients who met the criteria for further analysis, including 63 patients who had tumors located in the cervical esophagus and 348 patients with thoracic esophageal tumors.

In order to prevent selection bias for better comparison, the propensity score matching method was used among the 348 thoracic ESCC patients. First, we used binary logistic regression to calculate a propensity score, with covariates including age, gender, tumor T status, tumor N status, tumor stage, and tumor grade being entered into the propensity model.
Subsequently, a 1-to-1 match with the closest matching scores between the 63 cervical thoracic patients and 63 thoracic ESCC patients was determined. The algorithm used is shown in Figure 1.

Definition of inflammatory biomarkers and clinical tumor stage

In our study, chest computed tomography (CT), endoscopic ultrasonography (EUS), and positron emission tomography (PET) scans were performed for each patient, and the clinical tumor stage was determined according to the 7th American Joint Committee on Cancer (AJCC) staging system (Edge S et al., 2010). The definition of cervical esophageal cancer is that the tumor lies in the neck and is bordered superiorly by the hypopharynx and inferiorly by the thoracic inlet (sternal notch), approximately 15-20 cm from the incisors (Edge S et al., 2010).

Blood samples were obtained before treatment to measure the biomarkers of interest, which included the white blood cell count, platelet count, neutrophil count, lymphocyte count, albumin level, and CRP level. The NLR was calculated by dividing the neutrophil count by the lymphocyte count, and the PLR was defined as the platelet count divided by the lymphocyte count; the cut-off values for the NLR and PLR were 2.5 and 103, respectively (Dutta et al., 2011; Xie et al., 2016). The cut-off levels for CRP and albumin in this study were 10 mg/l and 3.5 g/dl,
respectively, with these levels being based on those used in previous studies (Forrest et al., 2003; McMillan, 2008; McMillan, 2013; McMillan et al., 2001). The mGPS was calculated using the CRP and albumin values and the scoring system was as follows: (1) patients with a normal CRP value (≤ 10 mg/l) were allocated a score of 0, regardless of the albumin level; (2) patients with a CRP level > 10 mg/l combined with an albumin level ≥ 3.5 g/dl were allocated a score of 1; (3) patients with a CRP > 10 mg/l and an albumin < 3.5 g/dl were allocated a score of 2 (McMillan, 2008). The optimal cut-off level for the CRP/albumin ratio was defined as 9.5 in the subsequent analysis (Wei et al., 2015). All the indicators involved in the calculation of the inflammation-based prognostic scores were examined before the patients underwent chemotherapy and radiotherapy.

**CCRT setting**

Curative intent radiotherapy was planned for each patient, and the details are described below. First, a customized thermoplastic immobilization device was designed. Subsequently, CT-simulation for image acquisition was performed. Inverse plan intensity-modulated radiotherapy (IMRT) was then used to deliver 6- or 10-MV photons to cover the treatment field,
including the neck and mediastinum. The gross target volume (GTV) was defined as the gross
tumor and gross lymph nodes (LNs) according to chest CT scan and/or PET-CT images. The
clinical target volume (CTV) comprehensively covered the esophagus, the mediastinal LNs, and
the supraclavicular LNs. The planning target volume (PTV) was defined as the CTV expanded
by 0.5-1.0 cm margins in all directions. The total doses prescribed to the PTV were 66-70 Gy in
33-35 daily fractions for cervical ESCC and 50-50.4 Gy in 25-28 daily fractions for thoracic
ESCC, followed by a boost dose to the gross neck LNs for an additional 10-16 Gy in 5-8 daily
fractions.

Chemotherapy was performed concurrently with radiotherapy and consisted of cisplatin
(75mg/m²; 4-hour infusion) on day 1 and 5-fluorouracil (1000mg/m²; continuous infusion) on
days 1-4 every 4 weeks. For patients with creatinine clearance < 60 mL/min, carboplatin was
used instead of cisplatin.

The technique above-mentioned was performed according to previously published studies
(Chen YH et al., 2017; Chen et al., 2017; Chen et al., 2018).

Statistical analysis
Comparisons between the groups were performed using the chi-square test for categorical variable data. A Cox regression model was used for univariate and multivariable analyses, and the hazard ratio (HR) and 95 confidence interval (CI) were computed with the Cox proportional hazards model. Overall survival (OS) was calculated from the date of diagnosis of the esophageal cancer to the date of death or last contact. The Kaplan–Meier method was used to estimate OS, and the log rank test was performed to evaluate the differences between the groups for univariate analysis. The statistical analyses were performed with the SPSS 19 software package (IBM, Armonk, NY). All of the tests were two-sided tests, and P < 0.05 was considered statistically significant.

Results

Patient characteristics

There were 411 locally advanced inoperable ESCC patients who completed CCRT with a curative intent at Kaohsiung Chang Gung Memorial Hospital who were retrospectively investigated in this study, including 63 cervical ESCC patients. All 63 cervical ESCC patients had an Eastern Cooperative Oncology Group performance status ≤ 1, and these patients consisted
of 61 male patients and 2 female patients with a median age of 58 years (range, 37-80 years). The tumor T status was revealed to be T2 in 1 patient (1.6%), T3 in 13 patients (20.6%), and T4 in 49 patients (77.8%). Meanwhile, five patients (7.9%) were diagnosed as having N0 status, 24 patients (38.1%) were diagnosed as having as having N1 status, 23 patients (36.5%) were diagnosed as having as having N2 status, and 11 patients (17.5%) were diagnosed as having as having N3 status. In terms of tumor stage, seven patients (11.1%) had stage IIIA, five patients (7.9%) had stage IIIB, and 51 patients (81.0%) had stage IIIC. Among the 63 patients, 14 patients (22.3%) were classified as grade 1, 36 patients (57.1%) as grade 2, and 13 patients (20.6%) as grade 3.

Using the propensity score matching method, 63 matched patients of the 348 thoracic ESCC patients were identified to compare to the 63 cervical ESCC patients. Parameters between these two groups were all matched without statistical difference, including tumor age, gender, T status, N status, tumor stage and tumor grade. The clinicopathological characteristics of these cervical and thoracic ESCC patients are shown in Table 1.

**Inflammation-based prognostic scores and clinical outcomes**
The inflammation-based prognostic scores used in our study included NLR, PLR, albumin value, CRP value, mGPS, and CRP/albumin ratio which were all well investigated in previous studies (Dutta et al., 2011; Feng et al., 2014; Forrest et al., 2003; McMillan, 2013; Miyata et al., 2011; Wei et al., 2015; Xie et al., 2016; Yodying et al., 2016). A total of 63 thoracic ESCC patients were identified to completely match the 63 cervical ESCC patients using the propensity score matching method. There were no significant differences in the baseline characteristics of these two groups, except for PLR (P=0.047). The comparison of inflammatory biomarkers in these cervical and thoracic ESCC patients are shown in Table 2.

With respect to cervical ESCC, NLR $\geq 2.5$ (P=0.019), PLR $\geq 103$ (P=0.013), CRP value $> 10$ (P=0.037), mGPS $\geq 1$ (P=0.037), and CRP/albumin ratio $\geq 9.5$ (P=0.033) were significant predictors of worse OS in the univariate analysis. Patients with NLR $\geq 2.5$ had worse OS compared to others with NLR $< 2.5$ (12.0 months versus 32.6 months, P=0.016, Figure 2A); and worse OS (11.6 months versus 25.3 months, P=0.010, Figure 2B) was also found in the 21 patients with PLR $\geq 103$ than the other 42 patients with PLR $<103$. The 35 patients with mGPS $\geq 1$ were found to have worse OS in comparison with the 28 patients with mGPS of 0 (12.0 months versus 25.3 months, P=0.037, Figure 2C); the total of 28 patients who had CRP/albumin ratio $\geq$
9.5 had worse OS compared to the other 35 patients who had CRP/albumin ratio < 9.5 (12.0 months versus 25.3 months, P=0.030, Figure 2D). In a multivariable analysis, PLR ≥ 103 (P=0.010, HR: 2.66, 95% CI: 1.27-5.58) and mGPS ≥ 1 (P=0.030, HR: 2.03, 95% CI: 1.07-3.86) were the independent prognostic parameters of worse OS.

With respect to thoracic ESCC, the univariate analysis showed that NLR ≥ 2.5 (P=0.041), PLR ≥ 103 (P=0.024), CRP value > 10 (P=0.001), mGPS ≥ 1 (P=0.001), and CRP/albumin ratio ≥ 9.5 (P=0.002) were still significant predictors of worse OS, similar to the results in the cervical ESCC group. Worse OS (9.0 months versus 14.4 months, P=0.038, Figure 3A) was also found in the 35 patients with ≥ 2.5 than the other 28 patients with NLR < 2.5; and patients with PLR ≥ 103 had worse OS compared to others with PLR <103 (9.0 months versus 10.9 months, P=0.022, Figure 3B). The total of 35 patients who had mGPS ≥ 1 had worse OS compared to the other 28 patients with mGPS of 0 (8.9 months versus 20.0 months, P=0.001, Figure 3C); the 28 patients who had CRP/albumin ratio ≥ 9.5 were found to have worse OS in comparison with the 35 patients who had CRP/albumin ratio < 9.5 (9.0 months versus 15.9 months, P=0.002, Figure 3D).

Patients with NLR ≥ 2.5 (P=0.012, HR: 2.21, 95% CI: 1.19-4.12) and mGPS ≥ 1 (P<0.001, HR:
3.13, 95% CI: 1.66-5.88) had worse OS than others with NLR < 2.5 and mGPS of 0 in the multivariable analysis. These univariate and multivariable survival analyses are shown in Table 3.

Discussion

Cervical ESCC is a small population of all esophageal cancer but is often locally advanced with nearby structures invasion at initial presentation (Yin et al., 1983). Although cervical ESCC only accounts for less than 10% of all cases, the management of this rare disease is very challenging. In the past, radical surgery with reconstruction was the gold standard of treatment, but the locally advanced status usually increased the difficulty of surgery, resulting in high mortality and morbidities (Grass et al., 2015). In the recently growing evidences have demonstrated that CCRT improved overall survival for ESCC patients, and more and more physicians preferred definitive CCRT rather than surgical resection for cervical ESCC patients in clinical practice (Cooper et al., 1999; Pignon et al., 2009). As far as we know, there were limited studies which focused on the outcome of cervical ESCC patients, and the predictive prognostic biomarkers for this group was still lack. However, accumulating evidences have revealed that inflammation-based prognostic scores, such as NLR, PLR, mGPS, etc., were associated with
clinical outcome in several cancer types, including esophageal cancer (Feng et al., 2014; Lindenmann et al., 2014; Pinato et al., 2014; Stotz et al., 2013; Templeton et al., 2014; Yodying et al., 2016). Therefore, the current study is designed to determine the role of these inflammation-based biomarkers in cervical ESCC patients.

Systemic inflammation plays an important role in the tumorigenesis, and the mechanism is very complicated. It may cause genetic mutations and instability, suppress antitumor immunity, decrease DNA repair function, and promote the formation of microenvironments, contributing to tumor initiation. In addition, it also induces tumor cell invasion, migration, metastasis and angiogenesis, resulting in tumor progression. The inflammatory factors are mainly derived from the secretion of both host and tumor cells, and the systemic reaction to cancer cells, including some chemokines and cytokines, transcription factors, CRP, circulating immunocytes, and so on (Balkwill, 2012; Elinav et al., 2013; Hoesel & Schmid, 2013; Nimptsch et al., 2015).

In the present study, we selected six biomarkers to evaluate the prognosis in the cervical ESCC patients, including NLR, PLR, CRP, albumin, mGPS and CRP/albumin ratio. Neutrophils play an important role in the systemic inflammation, and platelets are a critical source of chemokines/cytokines, and they both promote tumor progression through many different
pathways (Balkwill & Mantovani, 2001; Grivennikov et al., 2010). NLR and PLR were well
examined to predict the prognosis and have been frequently used in clinical practice in several
cancer types (Feng et al., 2013; Stotz et al., 2013; Templeton et al., 2014). CRP is a protein of
acute phase inflammation and has been reported to be associated with prognosis in esophageal
cancer patients (Nozoe et al., 2001). Albumin level is a good tool to evaluate the nutrition status
in cancer patients, and malnutrition is strongly correlated with worse treatment response and
poor prognosis (Hu et al., 2009). The scoring system of mGPS, reported by McMillan, has been
reported to be related to tumor size, lymph node metastasis, degree of tumor invasion, and
overall survival in ESCC patients (McMillan, 2008). The CRP/albumin ratio was initially
developed to predict clinical outcome and complications in patients with severe medical illness,
such as sepsis; after that, it was also indicated to predict prognosis in some cancer patients
(Ranzani et al., 2013; Wei et al., 2015). These biomarkers, such as complete blood
count/differential count, CRP, and albumin, are easy-to-measure, and most are usually
considered as routine pre-treatment tests in clinical practice.

The goal of treatment between thoracic and cervical ESCC is a little different. For cervical
ESCC patients, definitive CCRT is the more preferred therapeutic modality rather than surgical
resection due to high mortality and morbidities; therefore, higher radiotherapy dose (66-70 Gy)

was planned for these patients. In contrast, the radiotherapy dose for thoracic ESCC patients who
received CCRT is around 50 Gy. The different radiotherapy doses may result in different
treatment response of CCRT and prognosis; although there were limited evidences to discuss the
issue. Therefore, the role of inflammation-based prognostic scores for cervical and thoracic
ESCC may be different. In previous studies, these biomarkers were well investigated and defined
as prognostic factors in thoracic ESCC patients; however, the crucial role in cervical ESCC
patients was unclear (Dutta et al., 2011; Feng et al., 2014; McMillan, 2008; Miyata et al., 2011;
Wei et al., 2015; Xie et al., 2016; Yodying et al., 2016). The current study showed that NLR,
PLR, CRP, mGPS and CRP/albumin ratio were strongly correlated to poor prognosis in cervical
ESCC patients. Moreover, in order to correct for bias, the propensity score matching method was
used to select a control group from among the locally advanced thoracic ESCC patients who
received curative CCRT according to clinical tumor parameters (TNM stage, grade, sex and age)
in our hospital. The prognostic value of these biomarkers in the matched thoracic ESCC patients
was similar and compatible to the results in the cervical ESCC group in the univariate and
multivariable analyses.
Several studies have revealed that sex is an independent prognostic factor of overall survival in esophageal cancer (Chen et al., 2013; Cheng et al., 2018; Micheli et al., 2009). In Taiwan, the male/female incidence ratio of esophageal cancer was 16.2, and male patients were reported to have significant worse prognosis compared to female patients (Cheng et al., 2018). In the current study, there were only 2 female patients and the male/female ratio was 30.5; therefore, the effect of sex in the survival analysis may be minimal.

There are some limitations in our current study. First, the study only enrolled a small sample size, and all patients were treated at a single institution. Second, the study is a retrospective review, such that there may be selection bias. However, to be best of our knowledge, the current study is the first study to investigate the crucial role of inflammation-based prognostic scores in cervical ESCC patients. Furthermore, it comprises the largest series thus far of locally advanced cervical ESCC patients who underwent curative CCRT, and may be helpful to clarify the situation of this rare ESCC group.

Conclusions
Our study suggests that the inflammation-based prognostic scores are helpful in clinical practice, and PLR and mGPS may predict the prognosis for locally advanced cervical ESCC patients who receiving curative CCRT.

Acknowledgements

We appreciated the Biostatistics Center, Kaohsiung Chang Gung Memorial Hospital for statistics work.

References

National Department of Health, Republic of China. *Cancer Registry Annual Report 2015*.

Balkwill F, and Mantovani A. 2001. Inflammation and cancer: back to Virchow? *Lancet* 357:539-545. 10.1016/S0140-6736(00)04046-0

Balkwill FR. 2012. The chemokine system and cancer. *J Pathol* 226:148-157. 10.1002/path.3029

Chen MF, Yang YH, Lai CH, Chen PC, and Chen WC. 2013. Outcome of patients with esophageal cancer: a nationwide analysis. *Ann Surg Oncol* 20:3023-3030. 10.1245/s10434-013-2935-4
Chen YH LH, Wang YM, Lo CM, Chou SY, Huang CH, Shih LH, Chen SW and Li SH. 2017. The prognostic significance of celiac lymph node metastasis in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy. Oncotarget 8:96190-96202.

Chen YH, Lu HI, Chien CY, Lo CM, Wang YM, Chou SY, Su YY, Shih LH, and Li SH. 2017. Treatment Outcomes of Patients with Locally Advanced Synchronous Esophageal and Head/Neck Squamous Cell Carcinoma Receiving Curative Concurrent Chemoradiotherapy. Sci Rep 7:41785. 10.1038/srep41785

Chen YH, Lu HI, Lo CM, Wang YM, Chou SY, Huang CH, Shih LH, Chen SW, and Li SH. 2018. The clinical impact of supraclavicular lymph node metastasis in patients with locally advanced esophageal squamous cell carcinoma receiving curative concurrent chemoradiotherapy. PLoS One 13:e0198800. 10.1371/journal.pone.0198800

Cheng YF, Chen HS, Wu SC, Chen HC, Hung WH, Lin CH, and Wang BY. 2018. Esophageal squamous cell carcinoma and prognosis in Taiwan. Cancer Med. 10.1002/cam4.1499

Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA, Jr., Al-Sarraf M, Byhardt R, Russell AH, Beitle JI, Spencer S, Asbell SO, Graham MV, and Leichman LL. 1999.
Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. *JAMA* 281:1623-1627.

Dutta S, Crumley AB, Fullarton GM, Horgan PG, and McMillan DC. 2011. Comparison of the prognostic value of tumour- and patient-related factors in patients undergoing potentially curative resection of oesophageal cancer. *World J Surg* 35:1861-1866. 10.1007/s00268-011-1130-7

Edge S BD, Compton CC, Fritz AG, Greene FL and Trotti A. AJCC Cancer Staging Manual. 7th ed. New York: Springer-Verlag; 2010.

Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, and Flavell RA. 2013. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. *Nat Rev Cancer* 13:759-771. 10.1038/nrc3611

Feng JF, Huang Y, and Chen QX. 2014. Preoperative platelet lymphocyte ratio (PLR) is superior to neutrophil lymphocyte ratio (NLR) as a predictive factor in patients with esophageal squamous cell carcinoma. *World J Surg Oncol* 12:58. 10.1186/1477-7819-12-58

Feng JF, Huang Y, and Liu JS. 2013. Combination of neutrophil lymphocyte ratio and platelet
lymphocyte ratio is a useful predictor of postoperative survival in patients with esophageal squamous cell carcinoma. *Onco Targets Ther* 6:1605-1612.

Forrest LM, McMillan DC, McArdle CS, Angerson WJ, and Dunlop DJ. 2003. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. *Br J Cancer* 89:1028-1030.

Grass GD, Cooper SL, Armeson K, Garrett-Mayer E, and Sharma A. 2015. Cervical esophageal cancer: a population-based study. *Head Neck* 37:808-814. 10.1002/hed.23678

Grivennikov SI, Greten FR, and Karin M. 2010. Immunity, inflammation, and cancer. *Cell* 140:883-899. 10.1016/j.cell.2010.01.025

Hoesel B, and Schmid JA. 2013. The complexity of NF-kappaB signaling in inflammation and cancer. *Mol Cancer* 12:86. 10.1186/1476-4598-12-86

Hu JY, Yi W, Xia YF, Gao J, Liu ZG, and Tao YL. 2009. [Impact of pretherapy body mass index on prognosis of nasopharyngeal carcinoma]. *Ai Zheng* 28:1043-1048.

Lindenmann J, Fink-Neuboeck N, Koesslbacher M, Pichler M, Stojakovic T, Roller RE, Maier A,
Anegg U, Smolle J, and Smolle-Juettner FM. 2014. The influence of elevated levels of C-reactive protein and hypoalbuminemia on survival in patients with advanced inoperable esophageal cancer undergoing palliative treatment. *J Surg Oncol* 110:645-650.

10.1002/jso.23711

Mantovani A, Allavena P, Sica A, and Balkwill F. 2008. Cancer-related inflammation. *Nature* 454:436-444. 10.1038/nature07205

McMillan DC. 2008. An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. *Proc Nutr Soc* 67:257-262.

10.1017/S0029665108007131

McMillan DC. 2013. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. *Cancer Treat Rev* 39:534-540.

10.1016/j.ctrv.2012.08.003

McMillan DC, Elahi MM, Sattar N, Angerson WJ, Johnstone J, and McArdle CS. 2001. Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. *Nutr Cancer* 41:64-69.

10.1080/01635581.2001.9680613
Micheli A, Ciampichini R, Oberaigner W, Ciccolallo L, de Vries E, Izarzugaza I, Zambon P, Gatta G, De Angelis R, and Group EW. 2009. The advantage of women in cancer survival: an analysis of EUROCASE-4 data. *Eur J Cancer* 45:1017-1027. 10.1016/j.ejca.2008.11.008

Miyata H, Yamasaki M, Kurokawa Y, Takiguchi S, Nakajima K, Fujiwara Y, Mori M, and Doki Y. 2011. Prognostic value of an inflammation-based score in patients undergoing pre-operative chemotherapy followed by surgery for esophageal cancer. *Exp Ther Med* 2:879-885. 10.3892/etm.2011.308

Nimptsch K, Aleksandrova K, Boeing H, Janke J, Lee YA, Jenab M, Bueno-de-Mesquita HB, Jansen EH, Tsilidis KK, Trichopoulou A, Weiderpass E, Wu C, Overvad K, Tjonneland A, Boutron-Ruault MC, Dossus L, Racine A, Kaaks R, Canzian F, Lagiou P, Trichopoulos D, Palli D, Agnoli C, Tumino R, Vineis P, Panico S, Johansson A, Van Guelpen B, Khaw KT, Wareham N, Peeters PH, Quiros JR, Vencesla Garcia A, Molina-Montes E, Dorronsoro M, Chirlaque MD, Barricarte Gurrea A, Key TJ, Duarte-Salles T, Stepien M, Gunter MJ, Riboli E, and Pischon T. 2015. Association of CRP genetic variants with blood concentrations of C-reactive protein and colorectal cancer risk. *Int J*
Nozoe T, Saeki H, and Sugimachi K. 2001. Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. *Am J Surg* 182:197-201.

Pignon JP, le Maitre A, Maillard E, Bourhis J, and Group M-NC. 2009. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. *Radiother Oncol* 92:4-14. 10.1016/j.radonc.2009.04.014

Pinato DJ, Shiner RJ, Seckl MJ, Stebbing J, Sharma R, and Mauri FA. 2014. Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer. *Br J Cancer* 110:1930-1935. 10.1038/bjc.2014.145

Ranzani OT, Zampieri FG, Forte DN, Azevedo LC, and Park M. 2013. C-reactive protein/albumin ratio predicts 90-day mortality of septic patients. *PLoS One* 8:e59321. 10.1371/journal.pone.0059321

Sharaiha RZ, Halazun KJ, Mirza F, Port JL, Lee PC, Neugut AI, Altorki NK, and Abrams JA. 2011. Elevated preoperative neutrophil:lymphocyte ratio as a predictor of postoperative disease recurrence in esophageal cancer. *Ann Surg Oncol* 18:3362-3369. 10.1245/s10434-
Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. *Br J Cancer* 109:416-421.

Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T, Seruga B, Ocana A, Tannock IF, and Amir E. 2014. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. *Cancer Epidemiol Biomarkers Prev* 23:1204-1212. 10.1158/1055-9965.EPI-14-0146

Wei XL, Wang FH, Zhang DS, Qiu MZ, Ren C, Jin Y, Zhou YX, Wang DS, He MM, Bai L, Wang F, Luo HY, Li YH, and Xu RH. 2015. A novel inflammation-based prognostic score in esophageal squamous cell carcinoma: the C-reactive protein/albumin ratio. *BMC Cancer* 15:350. 10.1186/s12885-015-1379-6

Xie X, Luo KJ, Hu Y, Wang JY, and Chen J. 2016. Prognostic value of preoperative platelet-lymphocyte and neutrophil-lymphocyte ratio in patients undergoing surgery for
esophageal squamous cell cancer. *Dis Esophagus* 29:79-85. 10.1111/dote.12296

Yin WB, Zhang L, Miao Y, Yu Z, Zhang Z, Zhueng C, Wang M, Li G, Liu Y, Jia Y, and Ku X. 1983. The results of high-energy electron therapy in carcinoma of the oesophagus compared with telecobalt therapy. *Clin Radiol* 34:113-116.

Yodying H, Matsuda A, Miyashita M, Matsumoto S, Sakurazawa N, Yamada M, and Uchida E. 2016. Prognostic Significance of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Oncologic Outcomes of Esophageal Cancer: A Systematic Review and Meta-analysis. *Ann Surg Oncol* 23:646-654. 10.1245/s10434-015-4869-5

Yoo EJ, Park JC, Kim EH, Park CH, Shim CN, Lee HJ, Chung HS, Lee H, Shin SK, Lee SK, Lee CG, and Lee YC. 2014. Prognostic value of neutrophil-to-lymphocyte ratio in patients treated with concurrent chemoradiotherapy for locally advanced oesophageal cancer. *Dig Liver Dis* 46:846-853. 10.1016/j.dld.2014.05.009
Table 1 (on next page)

Clinicopathological parameters in 126 locally advanced cervical/thoracic esophageal SCC patients receiving curative CCRT
Table 1. Clinicopathological parameters in 126 locally advanced cervical/thoracic esophageal SCC patients receiving curative CCRT

| Characteristics | #Cervical esophageal SCC group (N=63) | #Thoracic esophageal SCC group (N=63) | P value |
|-----------------|--------------------------------------|---------------------------------------|---------|
| Age             |                                      |                                       |         |
| < 60 years      | 37 (58.7%)                           | 37 (58.7%)                           | 1.0     |
| ≥ 60 years      | 26 (41.3%)                           | 26 (41.3%)                           |         |
| Sex             |                                      |                                       |         |
| Male            | 61 (96.8%)                           | 61 (96.8%)                           | 1.0     |
| Female          | 2 (3.2%)                             | 2 (3.2%)                             |         |
| T status        |                                      |                                       |         |
| 2               | 1 (1.6%)                             | 1 (1.6%)                             | 1.0     |
| 3               | 13 (20.6%)                           | 13 (20.6%)                           |         |
| 4               | 49 (77.8%)                           | 49 (77.8%)                           |         |
| N status        |                                      |                                       |         |
| 0               | 5 (7.9%)                             | 5 (7.9%)                             | 1.0     |
| 1               | 24 (38.1%)                           | 24 (38.1%)                           |         |
| 2               | 23 (36.5%)                           | 23 (36.5%)                           |         |
| 3               | 11 (17.5%)                           | 11 (17.5%)                           |         |
| Stage           |                                      |                                       |         |
| IIIA            | 7 (11.1%)                            | 7 (11.1%)                            | 1.0     |
| IIIB            | 5 (7.9%)                             | 5 (7.9%)                             |         |
| IIIC            | 51 (81.0%)                           | 51 (81.0%)                           |         |
| Grade           |                                      |                                       |         |
| 1               | 14 (22.3%)                           | 14 (22.3%)                           | 1.0     |
| 2               | 36 (57.1%)                           | 36 (57.1%)                           |         |
| 3               | 13 (20.6%)                           | 13 (20.6%)                           |         |

SCC: squamous cell carcinoma; CCRT: concurrent chemoradiotherapy; #Using propensity score matching method. *Statistically significant.
Table 2 (on next page)

Comparison of inflammation-based prognostic scores in 126 locally advanced cervical/thoracic esophageal SCC patients receiving curative CCRT
Table 2. Comparison of inflammation-based prognostic scores in 126 locally advanced cervical/thoracic esophageal SCC patients receiving curative CCRT

| Characteristics                  | #Cervical esophageal SCC group (N=63) | #Thoracic esophageal SCC group (N=63) | P value |
|----------------------------------|--------------------------------------|----------------------------------------|---------|
| Neutrophil lymphocyte ratio      |                                      |                                        |         |
| < 2.5                            | 28 (44%)                             | 19 (30%)                               | 0.097   |
| ≥ 2.5                            | 35 (56%)                             | 44 (70%)                               |         |
| Platelet lymphocyte ratio        |                                      |                                        |         |
| < 103                            | 42 (67%)                             | 31 (49%)                               | 0.047*  |
| ≥ 103                            | 21 (33%)                             | 32 (51%)                               |         |
| Albumin                          |                                      |                                        |         |
| < 3.5                            | 9 (14%)                              | 12 (19%)                               | 0.473   |
| ≥ 3.5                            | 54 (86%)                             | 51 (81%)                               |         |
| CRP                              |                                      |                                        |         |
| ≤ 10                             | 28 (44%)                             | 21 (33%)                               | 0.201   |
| > 10                             | 35 (56%)                             | 42 (67%)                               |         |
| mGPS                             |                                      |                                        |         |
| 0                                | 28 (44%)                             | 21 (33%)                               | 0.201   |
| 1 + 2                            | 35 (56%)                             | 42 (67%)                               |         |
| CRP/Albumin ratio                |                                      |                                        |         |
| < 9.5                            | 35 (56%)                             | 34 (54%)                               | 0.858   |
| ≥ 9.5                            | 28 (44%)                             | 29 (46%)                               |         |

SCC: squamous cell carcinoma; CCRT: concurrent chemoradiotherapy; CRP: C-reactive protein; mGPS: modified Glasgow Prognostic Score. #Using propensity score matching method. *Statistically significant.
Table 3 (on next page)

Univariate and multivariable analysis of overall survival in 126 locally advanced cervical/thoracic esophageal SCC patients receiving curative CCRT
Table 3. Univariate and multivariable analysis of overall survival in 126 locally advanced cervical/thoracic esophageal SCC patients receiving curative CCRT

| Characteristics                  | Cervical esophageal SCC group | Thoracic esophageal SCC group |
|----------------------------------|-------------------------------|-------------------------------|
|                                  | Univariate analysis           | Multivariable analysis        |
|                                  | HR (95% CI)                   | P value                       | HR (95% CI)       | P value |
| Neutrophil lymphocyte ratio ≥ 2.5| 2.19 (1.14 - 4.20)            | 0.019*                        | 1.87 (1.03 - 3.42) | 0.041* |
| Platelet lymphocyte ratio ≥ 103  | 2.51 (1.22 - 5.17)            | 0.013*                        | 1.89 (1.09 - 3.28) | 0.024* |
| Albumin ≥ 3.5                    | 0.70 (0.31 - 1.61)            | 0.404                         | 0.68 (0.35 - 1.32) | 0.246  |
| CRP > 10                         | 1.95 (1.03 - 3.69)            | 0.037*                        | 2.78 (1.50 - 5.15) | 0.001* |
| mGPS ≥ 1                         | 1.95 (1.03 - 3.69)            | 0.037*                        | 2.78 (1.50 - 5.15) | 0.001* |
| CRP/Albumin ratio ≥ 9.5          | 1.96 (1.06 - 3.64)            | 0.033*                        | 2.42 (1.38 - 3.24) | 0.002* |

*Significant at p < 0.05
CCRT: concurrent chemoradiotherapy; HR: hazard ratio; CI: confidence interval; CRP: C-reactive protein; mGPS: modified Glasgow Prognostic Score. #Using propensity score matching method. *Statistically significant.
Figure 1

Algorithm for identifying locally advanced cervical and thoracic esophageal squamous cell carcinoma (ESCC) patients

- **Inclusion:**
  1. Squamous cell carcinoma
  2. Stage III disease
  3. Completing concurrent chemoradiotherapy (CCRT) as curative treatment
  4. Survive > 3 months after CCRT

- **Exclusion:**
  1. Distant metastasis
  2. Celiac lymph node metastasis
  3. History of second primary malignancy
  4. Acute or chronic infection/inflammation

- 411 ESCC patients completing CCRT

- 63 Cervical ESCC patients
- 348 Thoracic ESCC patients

- Using propensity score matching method

- 63 matched Thoracic ESCC patients
Figure 2

Comparison of overall survival curves of cervical esophageal squamous cell carcinoma patients according to different inflammation-based prognostic scores.

(A) Neutrophil lymphocyte ratio (NLR). (B) Platelet lymphocyte ratio (PLR) (C) Modified Glasgow prognostic score (mGPS). (D) CRP/albumin ratio.
Figure 3

Comparison of overall survival curves of thoracic esophageal squamous cell carcinoma patients according to different inflammation-based prognostic scores.

(A) Neutrophil lymphocyte ratio (NLR). (B) Platelet lymphocyte ratio (PLR) (C) Modified Glasgow prognostic score (mGPS). (D) CRP/albumin ratio.